In this direction, IL-6 inhibitors have been reported to reduce the odds of COVID-19 mortality (Sinha et al., 2021), and specific probiotic administration has been proposed to balance microbiome dysbiosis and prevent the development of virus-induced respiratory diseases (Wang et al., 2016) and may represent a possible intervention in COVID-19 patients. Here, IL6 is linked to respiratory system disorder.